Annovis Bio, Inc.
ANVS- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001477845
No open-market purchases or sales by Annovis Bio, Inc. insiders were filed in the last 90 days; 61 institutions reported holding it in 13F filings for Q2 2026, worth $20.2M in total; no superinvestor holds it.
13F holders, Q4 2022
Institutional positions in Annovis Bio, Inc. as of Dec 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 23
- −2 vs. Q3 2022
- Shares held
- 740.9K
- +3.19K (+0.4%) vs. Q3 2022
- Total value
- $9.93M
- −$107.4K (−1.1%) vs. Q3 2022
- New holders
- 2
- 5 more added
- Sold out
- 4
- 5 more reduced
Compare with Q3 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ANVS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 61 | $20.2M |
| Q1 2026 | 56 | $10.5M |
| Q4 2025 | 53 | $14.7M |
| Q3 2025 | 42 | $4.19M |
| Q2 2025 | 42 | $3.93M |
| Q1 2025 | 44 | $3.13M |
| Q4 2024 | 40 | $7.93M |
| Q3 2024 | 35 | $9.50M |
| Q2 2024 | 31 | $5.67M |
| Q1 2024 | 31 | $14.3M |
| Q4 2023 | 36 | $22.5M |
| Q3 2023 | 30 | $10.6M |
| Q2 2023 | 28 | $18.3M |
| Q1 2023 | 23 | $11.6M |
| Q4 2022 | 23 | $9.93M |
| Q3 2022 | 25 | $10.0M |
| Q2 2022 | 26 | $8.73M |
| Q1 2022 | 24 | $11.9M |
| Q4 2021 | 32 | $19.6M |
| Q3 2021 | 38 | $36.2M |
| Q2 2021 | 57 | $109.0M |
| Q1 2021 | 31 | $23.1M |
Institutions, Q4 2022
Shares, value and share of portfolio for each institution holding Annovis Bio, Inc.; share changes are against Q3 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Financial Connections Group, Inc. | 25 | $0 | 0.00% | 00.0% | Unchanged |
| Citigroup Inc | 6 | $81 | 0.00% | 00.0% | Unchanged |
| Rockefeller Capital Management L.P. | 1,000 | $13.0K | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 1,074 | $14.4K | 0.00% | −917−46.1% | Reduced |
| Tower Research Capital LLC (TRC) | 1,525 | $21.0K | 0.00% | −165−9.8% | Reduced |
| IFP Advisors, Inc | 4,600 | $44.0K | 0.00% | 00.0% | Unchanged |
| Advisor Group Holdings, Inc. | 3,366 | $45.0K | 0.00% | +86+2.6% | Added |
| Wells Fargo & Company | 8,783 | $118.0K | 0.00% | +10.0% | Added |
| Cannell Peter B & Co Inc | 10,000 | $134.3K | 0.00% | 00.0% | Unchanged |
| Koshinski Asset Management, Inc. | 10,000 | $134.3K | 0.01% | 00.0% | Unchanged |
| State Street Corp | 17,135 | $230.1K | 0.00% | 00.0% | Unchanged |
| Bridgeway Capital Management, LLC | 23,600 | $316.9K | 0.01% | 00.0% | Unchanged |
| Dimensional Fund Advisors LP | 24,860 | $334.0K | 0.00% | +24,860 | New |
| Morgan Stanley | 29,656 | $398.3K | 0.00% | −11,631−28.2% | Reduced |
| Modera Wealth Management, LLC | 30,513 | $409.8K | 0.02% | 00.0% | Unchanged |
| Sterling Investment Advisors, Ltd. | 32,474 | $436.1K | 0.16% | 00.0% | Unchanged |
| Redmond Asset Management, LLC | 34,010 | $456.8K | 0.16% | +34,010 | New |
| Bank of New York Mellon Corp | 34,223 | $459.6K | 0.00% | −106−0.3% | Reduced |
| Wescott Financial Advisory Group, LLC | 41,607 | $558.8K | 0.12% | 00.0% | Unchanged |
| Merit Financial Group, LLC | 43,150 | $579.5K | 0.02% | +23,150+115.8% | Added |
| Geode Capital Management, LLC | 43,558 | $584.0K | 0.00% | +1,262+3.0% | Added |
| BlackRock Inc. | 103,196 | $1.39M | 0.00% | −41,253−28.6% | Reduced |
| Vanguard Group Inc | 242,571 | $3.26M | 0.00% | +1100.0% | Added |
| Two Sigma Advisers, LP | 0 | $0 | 0.00% | −11,800−100.0% | Sold out |
| Knoll Capital Management, LLC | 0 | $0 | 0.00% | −14,210−100.0% | Sold out |
| High Net Worth Advisory Group LLC | 0 | $0 | 0.00% | −200−100.0% | Sold out |
| Royal Bank of Canada | 0 | $0 | 0.00% | −4−100.0% | Sold out |